12:00 AM
Jan 23, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tykerb: Phase III data

Researchers at Massachusetts General Hospital Cancer Center and colleagues reported data from the open-label, international Phase III NeoALTTO trial in 455 HER2-positive primary breast cancer patients with tumors >2 cm in diameter showing that a significantly greater proportion of patients receiving Herceptin trastuzumab plus Tykerb lapatinib achieved a pCR at the time of surgery, the primary endpoint, vs. Herceptin alone (51.3% vs. 29.5%, p=0.0001). pCR was defined as no invasive cancer in the breast or only non-invasive in situ...

Read the full 384 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >